

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Sheet

1

of

7

2

Application Number	10/660.069
--------------------	------------

Filing Date	09/11/2003
-------------	------------

First Named Inventor	HAYES et al.
----------------------	--------------

Art Unit	1646 1647
----------	----------------------

Examiner Name	Sandra Wegert
---------------	---------------

Attorney Docket Number	5853-283
------------------------	----------

[illegible][illegible]

**Examiner
Signature**

/Sandra Wegert/

Date
Considered

05/14/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/660,069
		Filing Date	09/11/2003
		First Named Inventor	HAYES et al.
		Art Unit	4646 1647
		Examiner Name	Sandra Wegert
Sheet <input checked="" type="checkbox"/> 2	of <input checked="" type="checkbox"/> 2	Attorney Docket Number	5853-283


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/SLW/		GIZA et al., "The Neurometabolic Cascade of Concussion," Journal of Athletic Training, 36:228-235, 2001.	

Examiner Signature	/Sandra Wegert/	Date Considered	05/14/2007
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/660,069
Filing Date	September 11, 2003
First Named Inventor	Ronald L. Hayes
Art Unit	1647
Examiner Name	Sandra Wegert
Attorney Docket Number	UF-530XT

Sheet

1

of

3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/SLW/	U1	US 5,536,639	07-16-1996	Siman, et al.	all
/SLW/	U2	US 5,118,606	06-02-1992	Lynch, et al.	all
	U3				
	U4				
	U5				
	U6				
	U7				
	U8				
	U9				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
/SLW/	F1	WO 95/26506	10-05-1995	Cephalon, Inc.	ALL	
	F2					
	F3					
	F4					

Examiner
Signature

/Sandra Wegert/

Date

Considered

05/14/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/660,069	
			Filing Date	September 11, 2003	
			First Named Inventor	Ronald L. Hayes	
			Group Art Unit	1647	
			Examiner Name	Sandra Wegert	
Sheet	2	of	3	Attorney Docket Number	UF-530XT

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
/SLW/	R1	PIKE, BRIAN R., <i>et al.</i> : "Accumulation of non-erythroid alphaII-spectrin and calpain-cleaved alphaII-spectrin breakdown products in cerebrospinal fluid after traumatic brain injury in rats", <i>Journal of Neurochemistry</i> , September 2001, pp 1297-1306, Vol. 78, No. 6.		
/SLW/	R2	NATH, RATHNA, <i>et al.</i> : "Non-erythroid alpha-spectrin breakdown by calpain and interleukin 1beta-converting-enzyme-like protease(s) in apoptic cells: contributory roles of both protease families in neuronal apoptosis", <i>Biochemistry Journal</i> , November 1, 1996, pp. 683-690, Vol. 319.		
/SLW/	R3	LI, ZHAOZHAO, <i>et al.</i> : "Peptide alpha-Keto Ester, alpha-Keto Amide, and alpha-Keto Acid Inhibitors of Calpains and Other Cysteine Proteases", <i>Journal of Medicinal Chemistry</i> , October 29, 1993, pp. 3472-80, Vol. 36, No. 22.		
/SLW/	R4	YOKOTA, M., <i>et al.</i> : "Three distinct phases of fodrin proteolysis induced in postischemic hippocampus - involvement of calpain and unidentified protease", <i>Stroke</i> , October 1995, pp. 1901-1907, Vol. 26, No. 10.		
/SLW/	R5	NATH, RATHNA, <i>et al.</i> : "Development and characterization of antibodies specific to caspase-3-produced alpha II-spectrin 120 kDa breakdown product: marker for neuronal apoptosis", <i>Neurochemistry International</i> , 2000, pp. 351-361, Vol. 37.		
/SLW/	R6	PIKE, BRIAN R., <i>et al.</i> : "Regional calpain and caspase-3 proteolysis of alpha-spectrin after traumatic brain injury", <i>NeuroReport</i> , August 3, 1998, pp. 2437-42, Vol. 9, No. 11.		
/SLW/	R7	ZHAO, X., <i>et al.</i> : "Maitotoxin Induces Calpain But Not Caspase-3 Activation and Necrotic Cell Death in Primary Septo-Hippocampal Cultures", <i>Neurochemical Research</i> , 1999, pp. 371-382, Vol. 24, No. 3.		
/SLW/	R8	PIKE, BRIAN R., <i>et al.</i> : "Temporal Relationships Between De Novo Protein Synthesis, Calpain and Caspase 3-like Protease Activation, and DNA Fragmentation During Apoptosis in Septo-Hippocampal Cultures", <i>Journal of Neuroscience Research</i> , 1998, pp. 505-520, Vol. 52.		
/SLW/	R9	GIZA, CHRISTOPHER C., <i>et al.</i> : "The Neurometabolic Cascade of Concussion", <i>Journal of Athletic Training</i> , September 2001, pp. 228-235, Vol. 36, No. 3.		
/SLW/	R10	MCGINNIS, KIM M., <i>et al.</i> , "Alterations of Extracellular Calcium Elicit Selective Modes of Cell Death and Protease Activation in SH-SY5Y Human Neuroblastoma Cells", <i>Journal of Neurochemistry</i> , 1999, pps. 1853-63, Vol. 72, No. 5, Lippincott Williams & Wilkins, Inc., Philadelphia, PA.		

Examiner Signature	/Sandra Wegert/	Date Considered	05/14/2007
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/660,069	
			Filing Date	September 11, 2003	
			First Named Inventor	Ronald L. Hayes	
			Group Art Unit	1647	
			Examiner Name	Sandra Wegert	
			Attorney Docket Number	UF-530XT	
Sheet	3	of	3		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/SLW/	R1	NATH, RATHNA, <i>et al.</i> : "Activation of apoptosis-linked caspase(s) in NMDA-injured brains in neonatal rats", <i>Neurochemistry International</i> , 2000, pp. 119-126, Vol. 36.	
/SLW/	R2	BARTUS, RAYMOND T., <i>et al.</i> "Time-Related Neuronal Changes Following Middle Cerebral Artery Occlusion: Implications for Therapeutic Intervention and the Role of Calpain," <i>Journal of Cerebral Blood Flow and Metabolism</i> , November 1995, pp. 969-79, Vol. 15, No. 6, Lippincott-Raven Publishers, Philadelphia, PA.	
/SLW/	R3	Supplementary Partial European Search Report	
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		

Examiner Signature	/Sandra Wegert/	Date Considered	05/14/2007
--------------------	-----------------	-----------------	------------



PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/660,069
Filing Date	September 11, 2003
First Named Inventor	Ronald L. Hayes
Group Art Unit	1647
Examiner Name	Sandra Wegert
Attorney Docket Number	UF-530XT

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/SLW/	R1	WANG, KEVIN K.W., <i>et al.</i> , "Simultaneous Degradation of α II and β II-Spectrin by Caspase 3 (CPP32) in Apoptotic Cells", <i>The Journal of Biological Chemistry</i> , August 28, 1998, pp. 22490-22497, Vol. 273, No. 35, The American Society for Biochemistry and Molecular Biology, Inc., U.S.A.	
	R2		
	R3		
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		

Examiner
Signature

/Sandra Wegert/

Date
Considered

05/14/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.